Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents

To evaluate the diagnostic performance (primary) and safety (secondary) of seven T.R.U.E.
Test Panel allergens; Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin,
Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol in pediatric
subjects 6-17 years of age with suspected contact dermatitis based on symptoms and clinical
history.

Inclusion Criteria:

- Symptoms and history potentially consistent with allergic contact dermatitis

- Children and adolescents 6-17 years of age, in general good health

- Adolescent females 15 years of age or older (or with menarche) must consent to a
urine pregnancy test; urine test results must be negative for study inclusion

- Informed consent must be signed and understood by subject. If underage, informed
consent must be signed and understood by parent or legal guardian, consistent with
all institutional, local and national regulations

Exclusion Criteria:

- Topical corticosteroid treatment during the last 7 days on or near the test area.

- Systemic treatment with corticosteroids or other immunosuppressives during the last 7
days.

- Subjects currently receiving (or received during the previous 3 weeks) other
investigational drugs, treatments or devices, or participating in another clinical
study

- Treatment with ultraviolet (UV) light (including tanning) during the previous 3 weeks

- Acute dermatitis outbreak or dermatitis on or near the test area on the back

- Subjects unable to comply with activity restrictions (e.g. protecting test panels
from excess moisture due to showering or vigorous activity)

- Subjects unable or unwilling to comply with multiple return visits

- Female subjects 15 years of age (or with onset of menarche) and older unable to
consent to a urine pregnancy test, or those with a positive pregnancy test